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ﬁrst clinically isolated event (CIS), with a high probability of
progressing to clinical deﬁnite multiple sclerosis (CDMS). We
evaluated the long-term cost-effectiveness of treating CIS
patients with interferon-b-1b (IFNB-1b) to delay conversion to
CDMS and subsequent disease progression. METHODS: A
Markov model was developed to estimate the cost-effectiveness
of IFNB-1b compared to no treatment based on a double blind
2-year trial (BENEFIT). Data from the MS registries in Stock-
holm (Sweden) and in Lyon (France) were used to populate the
model in addition to efﬁcacy data from the clinical trial.
Patients converting to CDMS are eligible for any of the licensed
disease-modifying drugs (DMD) and disease progression under
active treatment is estimated using the treated patients in the
Stockholm MS Registry. Patients withdrawing from treatment
during or after the trial follow the disease progression of
patients not on DMDs in the Lyon MS registry (EDMUS).
Disease development is expressed as moving from CIS to mild,
moderate and severe disability. Costs and utilities are assigned
to patients based on observational data from the Stockholm
area. Results are presented as cost per quality-adjusted life-
years (QALYs) gained, from the societal perspective, in 2006 €.
RESULTS: Including all patients, the cost per QALY gained
with IFNB-1b is 33,185 € over 20 years. For patients with a
mono-focal CIS, prevention with IFNB-1b dominates no treat-
ment, with cost-savings of 13,338 € for a QALY gain of 0.29
(both discounted with 3%). Results are sensitive to the time
horizon, the treatment duration and proportion of patients
treated at conversion, and the perspective of the analysis.
CONCLUSION: Within the framework of this analysis in
Sweden, around 35% of estimates are cost-saving and more
than half of cost-effectiveness ratios remain below a threshold
of 50,000 € under most assumptions.
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OBJECTIVES: To assess the cost-effectiveness of using a
lidocaine 5% medicated plaster in the treatment of post-herpetic
neuralgia (PHN) compared with generic gabapentin (1800 mg/
day; 1200 mg/day with add-in-medication) and pregabalin
(PG; 300 mg/day and 600 mg/day; 300 mg/day with add-in-
medication) from the perspective of the German Sickness Funds.
METHODS: A Markov model was constructed to calculate the
cost-effectiveness of gabapentin, PG and lidocaine plaster in
terms of the cost per quality-adjusted life-year (QALY) gained
when used over a six-month time horizon in patients with PHN.
The model structure allowed for differences in costs, utilities and
transition probabilities between the initial 30-day run-in period
and maintenance therapy. Most transition probabilities were
based on clinical trials identiﬁed through a systematic literature
review. Missing data, including resource utilization, were
obtained from a Delphi panel and cost data were from ofﬁcial
price tariffs/lists. Utilities derived from the literature were
adjusted for age, and were supplemented and validated by the
Delphi panel. RESULTS: The total cost of treatment with the
lidocaine plaster was €937 per patient, compared with €728
for generic gabapentin, €875 for PG300 mg and €975 for
PG600 mg. Lidocaine plaster generated 0.300 QALYs, compared
with 0.247 for gabapentin, 0.253 for PG300 mg and 0.256
for PG600 mg. Lidocaine plaster therefore costs €3,943
(95% conﬁdence interval [95%CI]: €997, €10,034) per QALY
gained relative to gabapentin, €1,319/QALY (95%CI: domi-
nant, €10,032) relative to PG300 mg and dominated PG600 mg
(95%CI: dominant, €4,229). Probabilistic sensitivity analysis
demonstrated that at a €20,000/QALY threshold, the lidocaine
plaster is cost-effective relative to gabapentin with 99.75% con-
ﬁdence, 99.24% relative to PG300 mg and 99.42% relative to
PG600 mg. Scenario analyses and extensive one-way sensitivity
analyses on all parameters including the time horizon conﬁrmed
the robustness of the results. CONCLUSIONS: The lidocaine
5% plaster is a highly cost-effective treatment for PHN in
Germany.
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OBJECTIVES: Using a work-based survey, this study explored
the impact of sleep loss and insomnia on worker productivity
in diverse work populations. METHODS: Employees in four
diverse U.S.-based companies participated by completing an
anonymous, 55-item, online survey. Respondents were classiﬁed
according to DSM-IV-TR minimum criteria for ‘primary’ and
‘secondary’ insomnia (IN) and ICSD minimum criteria for
insufﬁcient sleep syndrome (ISS). The remaining respondents
were classiﬁed as either ‘at-risk’ (reported medical, psychologi-
cal or sleep conditions that precluded IN or ISS) or ‘good-sleep’
(did not meet criteria for any other group). Associated presen-
teeism was measured using the Work Limitations Question-
naire. Productivity loss to the employer was estimated using
company and/or industry-speciﬁc wage data. RESULTS: Of
4,188 respondents who completed the survey (40.0  11.2
years, 53.4% male), 9.6% (n = 403), 5.9% (n = 247), 39.6%
(n = 1660) and 44.8% (n = 1878) were classiﬁed as IN, ISS,
at-risk, and good-sleep, respectively. IN and ISS groups
reported the greatest impaired abilities (p < .05) in time
management (28.3%  22.5, 25.4%  22.2, 20.4%  19.6,
11.2%  14.5 for IN, ISS, at-risk and good-sleep, respectively),
mental-interpersonal demands (23.5%  18.1, 22.4%  19.0,
18.1%  17.1, 9.8%  11.7 for IN, ISS, at-risk and good-
sleep, respectively) and output demands (20.5%  20.0,
17.5%  19.2, 14.7%  17.8, 8.1%  12.6 for IN, ISS, at-risk
and good-sleep, respectively). Limitations in performing physi-
cal job demands was greatest for the IN group (18.3%  21.3,
p < .05) compared to all other groups (14.7%  18.7,
12.8%  18.4, 7.1%  14.1, for ISS, at-risk, and good-sleep,
respectively). Mean at-work productivity loss was 6.1%, 5.5%,
4.6%, 2.5%, for insomnia, ISS, at-risk and good-sleep groups,
respectively (p < .05). Based on each company’s annual salaries,
mean at-work productivity loss for the insomnia group was
$3,156/employee (range $2,531-$3,980). The aggregate pro-
ductivity loss to an employer was estimated to be $309,120.
CONCLUSION: The relatively high prevalence of sleep
disruptions within these companies coupled with the impact on
job performance and productivity loss provide a rationale
for improving detection and treatment among employed
individuals.
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